Opus Genetics Deal History & Licensing Activity
Opus Genetics is a life sciences. Over the past three years, Opus Genetics has been involved in 2 licensing and acquisition transactions, with a primary focus on Gene Therapy (4 deals). The company currently has 2 active clinical trials, primarily in Ophthalmology.
Deals (12mo)
1
Active Trials
2
Top Modality
Gene Therapy
Focus Area
Ophthalmology
Opus Genetics Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Opus Genetics in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| OPGx-RDH12 | Global RDH12 Alliance | Gene Therapy | Preclinical | collaboration | Jul 2025 |
| OPGx-RDH12 | Global RDH12 Alliance | Gene Therapy | Preclinical | collaboration | Jun 2025 |
Opus Genetics Pipeline Focus
Therapeutic areas and modalities where Opus Genetics is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Opus Genetics Strategic Signals
Key indicators of Opus Genetics's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Opus Genetics Clinical Pipeline
Opus Genetics has 2 active clinical trials across 1 development phase.
2
Phase 1
See How Your Asset Matches Opus Genetics's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Ophthalmology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Ophthalmology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for ophthalmology
Gene Therapy Benchmarks
Upfront, milestone, and royalty benchmarks for gene therapy deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Opus Genetics Licensing & Deal Activity
Opus Genetics is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Opus Genetics ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Opus Genetics include Ophthalmology (4 deals and trials). In terms of modality, Opus Genetics has shown particular interest in gene therapy.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Opus Genetics and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Opus Genetics's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.